Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

Fig. 2

a: Progression-free survival of patients receiving nabPGem as second-line therapy after FOLFIRINOX pre-treatment: median PFS: 3.2 months (95% CI: 0.4–6). b: Progression-free survival of patients receiving FOLFIRINOX as second-line therapy after nabPGem pre-treatment: 5.7 months (95% CI: 4.8–6.6)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us